Entrada Therapeutics Reports Q3 2026 Results, $193 Million in Cash

What happened

Entrada Therapeutics reported third-quarter 2026 collaboration revenue of $0.9 million and a net loss of $39.7 million. It had $193.0 million in cash, cash equivalents and marketable securities at September 30, 2026, which it expects to fund operations into the fourth quarter of 2027.

Confirmed

Global impact / market context

The reported cash runway gives investors a stated timeframe for funding operations, while the quarterly loss and low collaboration revenue show that current income did not cover reported expenses. If clinical programs require continued spending, the timing and results of upcoming data readouts could influence future costs and funding needs.

Analyst inference

Cash resources fell from $295.7 million at December 31, 2025, to $193.0 million at September 30, 2026. Research and development spending was $32.4 million for the quarter, while the company expects available funds to support operations into Q4 2027; this is management’s forecast, not a guarantee.

Confirmed

What to watch

1. Watch for the open-label ELEVATE-44-201 Cohort 1 data expected by year-end 2026; results could shape views of the program’s progress and subsequent development spending. Confirmed
2. Cohort 2 data are expected in Q1 2027, and enrollment is ongoing; follow whether the timing or enrollment status changes, since delays can extend development costs. Confirmed
3. Compare future cash balances and spending with the stated runway into Q4 2027; faster cash use could shorten that period and increase the importance of obtaining funding. Analyst inference

Evidence

• Original source link unavailable